Dare Bioscience Inc (DARE) Stock AnalysisDAREStock AnalysisDare Bioscience Inc

Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

DARE is not a good buy right now due to its current price of $0.73, a very low RSI of 20.05 indicating oversold conditions, and a staggering year-to-date decline of 62.31%. The company is facing significant financial challenges, including a negative gross margin of -70.57% in Q2 2026 and a warning about needing to raise capital, which adds to liquidity risks.

1 analysts cover DARE: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 10.00.